Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
BIOVIE INC (BIVI) Stock Price & Overview
NASDAQ:BIVI • US09074F5044
Current stock price
1.58 USD
-0.01 (-0.63%)
Last:
The current stock price of BIVI is 1.58 USD. Today BIVI is down by -0.63%. In the past month the price increased by 17.04%. In the past year, price decreased by -86.94%.
BIVI Key Statistics
52-Week Range1.06 - 13.2
Current BIVI stock price positioned within its 52-week range.
1-Month Range1.325 - 1.72
Current BIVI stock price positioned within its 1-month range.
- Market Cap
- 11.913M
- P/E
- N/A
- Fwd P/E
- 0.36
- EPS (TTM)
- -5.13
- Dividend Yield
- N/A
BIVI Stock Performance
Today
-0.63%
1 Week
N/A
1 Month
+17.04%
3 Months
+38.60%
Longer-term
6 Months -9.71%
1 Year -86.94%
2 Years -96.78%
3 Years -99.80%
5 Years -99.91%
10 Years N/A
BIVI Stock Chart
BIVI Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BIVI. When comparing the yearly performance of all stocks, BIVI is a bad performer in the overall market: 87.91% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
BIVI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BIVI. While BIVI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BIVI Earnings
Next Earnings DateMay 11, 2026
Last Earnings DateFeb 6, 2026
PeriodQ2 / 2026
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
BIVI Forecast & Estimates
7 analysts have analysed BIVI and the average price target is 12.24 USD. This implies a price increase of 674.68% is expected in the next year compared to the current price of 1.58.
Analysts
Analysts82.86
Price Target12.24 (674.68%)
EPS Next Y33.11%
Revenue Next YearN/A
BIVI Financial Highlights
Over the last trailing twelve months BIVI reported a non-GAAP Earnings per Share(EPS) of -5.13. The EPS increased by 87.03% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-17.48M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.67% | ||
| ROE | -90.72% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%83.17%
Sales Q2Q%N/A
EPS 1Y (TTM)87.03%
Revenue 1Y (TTM)N/A
BIVI Ownership
Ownership
Inst Owners15.64%
Shares7.54M
Float7.52M
Ins Owners0.3%
Short Float %1.72%
Short Ratio1.59
BIVI Industry Overview
BIVI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
66%
Outperformed 66% of sub-industries
3 Month Rank
48%
Outperformed 48% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.8%
- New Lows
- 3.1%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.2
- Average Fwd P/E
- 22.5
- Average Debt/Equity
- 2.1
BIVI Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.33 | 349.666B | ||
| AMGN | AMGEN INC | 14.87 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.08 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.61 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.26 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.37 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.47 | 24.944B | ||
| INCY | INCYTE CORP | 10.7 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BIVI
Company Profile
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Company Info
IPO: 2014-01-14
BIOVIE INC
680 W Nye Lane, Suite 201
Carson City NEVADA 90404 US
CEO: Cuong Do
Employees: 13
Phone: 17758883162
BIOVIE INC / BIVI FAQ
What does BIVI do?
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company is headquartered in Carson City, Nevada and currently employs 13 full-time employees. The company went IPO on 2014-01-14. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Can you provide the latest stock price for BIOVIE INC?
The current stock price of BIVI is 1.58 USD. The price decreased by -0.63% in the last trading session.
What is the dividend status of BIOVIE INC?
BIVI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BIVI stock?
BIVI has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What sector and industry does BIOVIE INC belong to?
BIOVIE INC (BIVI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for BIVI stock?
BIOVIE INC (BIVI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.13).